Home / Stocks / GL

Globe Life (GL, Life & Health Insurance) Stock Valuation & Fair Value Fairly valued

Globe Life (GL, Life & Health Insurance) trades at a blended P/E of 11.9 — about 2% below its historical normal valuation — with a forward growth estimate of 7.6% and a PEG of 1.56. Analysts' one-year estimates have been hit 82% of the time.

Blended P/E
11.9
Normal P/E
12.1
PEG
1.56
Fwd growth
7.6%
Div yield
0.7%

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-03.

2026-06-03P/E 10.3-15%Fairly valued
2026-06-10P/E 10.6-12%Fairly valued
2026-06-14P/E 10.6-12%Fairly valued
2026-06-16P/E 10.6-12%Fairly valued
2026-06-21P/E 10.6-12%Fairly valued
2026-07-02P/E 11.9-1%Fairly valued
2026-07-06P/E 12.0-1%Fairly valued
2026-07-09P/E 12.0-1%Fairly valued
2026-07-12P/E 11.9-2%Fairly valued
2026-07-13P/E 11.9-2%Fairly valued
2026-07-14P/E 11.9-2%Fairly valued ← now

Frequently asked questions

Is Globe Life stock overvalued?

At a blended P/E of 11.9 versus its historical normal P/E of 12.1, Globe Life trades about 2% below its typical valuation, with a PEG of 1.56 on 7.6% forward growth — tickerseer currently rates it fairly valued.

What is Globe Life's fair value and PEG?

Globe Life trades at a blended P/E of 11.9 against a historical normal P/E of 12.1, a PEG of 1.56, and a forward growth estimate of 7.6%.

Has tickerseer's rating of Globe Life changed?

tickerseer's rating has been fairly valued since 2026-06-03.

Industry: Life & Health Insurance. Create a free account to unlock the full analysis — the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.